ATAI
ATAI Life Sciences BVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.40B
P/E Ratio
—
EPS
$-0.83
Beta
1.57
52W High
$6.75
52W Low
$1.15
50-Day MA
$3.75
200-Day MA
$4.10
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About ATAI Life Sciences BV
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Fundamentals
| Revenue (TTM) | $4.09M |
| Gross Profit (TTM) | $-43.52M |
| EBITDA | $-110.22M |
| Operating Margin | -3588.00% |
| Return on Equity | -390.00% |
| Return on Assets | -30.70% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $0.61 |
| Price-to-Book | 8.62 |
| Price-to-Sales (TTM) | 341.98 |
| EV/Revenue | 419.13 |
| EV/EBITDA | 0.27 |
| Quarterly Earnings Growth (YoY) | -96.80% |
| Quarterly Revenue Growth (YoY) | 1773.00% |
| Shares Outstanding | $363.21M |
| Float | $302.85M |
| % Insiders | 3.68% |
| % Institutions | 31.40% |
Analyst Ratings
Consensus ($13.33 target)
2
Strong Buy11
BuyData last updated: 4/7/2026